Case Report: Two Rare Cases of Complete Metabolic Response to Crizotinib in Patients With Rearranged ROS1 and ALK Metastatic Non-small Lung Cancer

Karim Amrane; Luca Campedel; Coline Le Meur; Ronan Abgral; Dris Kharroubi; Jacques Cadranel

doi:10.3389/fmed.2021.691253

Case Report: Two Rare Cases of Complete Metabolic Response to Crizotinib in Patients With Rearranged ROS1 and ALK Metastatic Non-small Lung Cancer

Front Med (Lausanne). 2021 Sep 30:8:691253. doi: 10.3389/fmed.2021.691253. eCollection 2021.

Authors

Karim Amrane^{1

2}, Luca Campedel¹, Coline Le Meur², Ronan Abgral³, Dris Kharroubi⁴, Jacques Cadranel⁵

Affiliations

¹ Department of Oncology, Pitié Salpêtrière Hospital, Paris, France.
² Department of Oncology, Centre Hospitalier des Pays de Morlaix, Morlaix, France.
³ Department of Nuclear Medicine, University Hospital of Brest, Brest, France.
⁴ Department of Nuclear Medicine, Pitié Salpêtrière Hospital, Paris, France.
⁵ Department of Pneumology and Thoracic Oncology, Tenon Hospital, AP-HP and Sorbonne Université, Paris, France.

Abstract

Crizotinib is a tyrosine kinase inhibitor (TKI) indicated in first-line treatment of rearranged c-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK) metastatic non-small-cell lung cancer (NSCLC). However, the common response reported after treatment is partial and few complete responses have been reported in PROFILE studies with computed tomography (CT) evaluation. To date, only one case report of complete metabolic response on 2-deoxy-2-[¹⁸F] fluoro-D-glucose positron emission tomography-computed tomography (¹⁸F-FDG-PET/CT) was published, reporting on a patient with ROS1 rearranged NSCLC. We highlighted the ¹⁸F-FDG-PET/CT useful approach for therapeutic assessment of TKI in metastatic mutated NSCLC reporting two complete metabolic responses in patients treated with crizotinib for a rearranged ROS1 and a metastatic ALK NSCLC.

Keywords: ALK; FDG-PET/CT; NSCLC; ROS1; crizotinib; therapeutic assessment.

Publication types

Case Reports